rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FHLC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the Difference
      Oct 30Yahoo FinanceFHLC
      Which Healthcare ETF Is the Better Buy: Fidelity’s FHLC or State Street’s XLV? | The Motley Fool

      XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually.

      Oct 26The Motley FoolSTTFHLC
      Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? | The Motley Fool

      One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.

      Oct 11The Motley FoolIVZFHLC
      Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech | The Motley Fool

      Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.

      Oct 5The Motley FoolSTTFHLCXBI
      Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech
      Oct 4Yahoo FinanceFHLC
      Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure? | The Motley Fool

      FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.

      Sep 16The Motley FoolFHLCIXJ
      Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? | The Motley Fool

      One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

      Sep 10The Motley FoolFBTFHLC
      Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? | The Motley Fool

      FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.

      Sep 10The Motley FoolSTTFHLCXPH
      Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ | The Motley Fool

      Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

      Sep 2The Motley FoolIVZFHLC
      Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus | The Motley Fool

      VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.

      Aug 26The Motley FoolPPHFHLC

      This is the newest page. Registered accounts read further back.